☆ 4.2 Meeting Abstract

Long-Term Survival Projections of Loncastuximab Tesirine-Treated Patients in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

Journal

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

Volume 22, Issue -, Pages S373-S373

Publisher

CIG MEDIA GROUP, LP

Keywords

ABCL; health services; research; DLBCL; non-Hodgkin lymphoma; survival projection; loncastuximab tesirine; Phase II

Categories

Oncology Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.